Company Interview / Biotron's hepatitis breakthrough

Key points:

Biotron’s HBV treatment demonstrated significant efficacy to Tenofovir in preclinical studiesAcquisition of Sedarex brings a near-term general anaesthetic asset to the pipelineRegulatory milestones and possible fast market entry for the new anaesthetic expected within six monthsFunding support includes a $1 million placement and active rights issue

Biotron (ASX:BIT) has unveiled promising new data demonstrating progress in its hepatitis B virus (HBV) programme. Dr Michelle Miller reveals the company’s candidate treatment shows significant reductions in key markers of viral persistence in animal models. Miller indicates these results compare favourably to current standard therapy Tenofovir, which only suppresses HBV rather than achieving a cure. The company’s next step will be first-in-human trials, anticipated towards the end of 2026, with hopes of ultimately delivering more effective outcomes for patients.

Miller also outlines Biotron’s recent strategic acquisition of Sedarex Limited. This move diversifies the portfolio, bringing in a late-stage, de-risked general anaesthetic product that could reach the market much sooner than traditional biotech developments. Key regulatory milestones in Europe for this asset are expected within the next six months, potentially fast-tracking commercialisation and boosting shareholder value. Miller highlights these developments as crucial for weathering volatile market conditions and promising milestone news through 2026.

Financially, Biotron recently completed a $1 million placement led by Peak Asset Management and has launched a rights issue to further fund operations. Miller believes these steps position the company well for growth, with multiple catalysts ahead and a clear focus on antiviral innovation and portfolio expansion.